Lilly announced last week that its experimental treatment solanezumab failed to improve thinking skills, memory and function in a broad range of patients. At the same time, an unusual reanalysis of the data found the drug may slow mental decline in those with the mildest form of Alzheimer’s.
Investors responded on Aug. 24 by boosting Indianapolis- based Lilly 3.4 percent in New York trading. Current patients, though, found little solace in the result, said Samuel Gandy, director of Mount Sinai Center for Cognitive Health in New York.
Continue Reading -- Lilly’s Alzheimer Drug Finding Splits Investors